Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 3NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Burkitt Lymphoma 5Multiple Myeloma 4Lung Neoplasms 3Leukemia, Biphenotypic, Acute 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Carcinoma, Non-Small-Cell Lung 2Vomiting 1Smoldering Multiple Myeloma 1Recurrence 1Ovarian Neoplasms 1Nausea 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Down Syndrome 1Brenner Tumor 1

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1auricularum 1Myelography 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Smoldering Multiple Myeloma × auricularum × Clear all
NCT03937635 2026-05-15

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Eastern Cooperative Oncology Group

Phase 3 Recruiting
288 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡